Byetta Warning Issued By The FDA
Byetta and other suspect drugs should be promptly discontinued if pancreatitis is suspected. There are no known patient characteristics that can determine whether a case of pancreatitis associated with Byetta will develop into the hemorrhagic or necrotizing forms. If pancreatitis is confirmed, it should be treated without delay and the patient should be carefully monitored until recovery. Byetta should not be restarted. Physicians should consider antidiabetic therapies other than Byetta in patients who have a history of pancreatitis.
If you or a loved one has taken Byetta and had any adverse effects then you should call us toll free now at 1-866-374-0338 because you may be entitled to medical monitoring and compensation from the manufacturer.
We have represented clients in every state and helped thousands of injured clients nationwide make recoveries for their injuries. We are ready to help you! Our clients are never at risk of paying any fees, expenses, or costs out of pocket. All fees costs and expenses are paid only out of any recovery we make for you. Do not delay. Contact us now to find out if we can help. The claim evaluation is free. All claims have strict time limitations which will bar any recovery you or your loved may be entitled if the claim is not brought on time.
. | |||||
| |||||
 |
 |
Home
 Byetta FDA Warning Byetta FDA Warning |
Complete this form for a free claim evaluation |
In October 2007, FDA warned healthcare professionals about reports of acute pancreatitis in patients taking the antidiabetic drug Byetta (exenatide). Since then, FDA has received reports of six cases of hemorrhagic or necrotizing pancreatitis in patients taking Byetta. Two were fatal.
